Treatment of 131I-labeled anti-CD147 monoclonal antibody in VX2 carcinoma-induced liver tumors

Niu,Huanzhang; Wang,Ruihua; Cheng,Jingliang; Gao,Shegan; Liu,Baoping

doi:10.3892/or.2013.2418

Treatment of 131I-labeled anti-CD147 monoclonal antibody in VX2 carcinoma-induced liver tumors

Authors:
- Huanzhang Niu
- Ruihua Wang
- Jingliang Cheng
- Shegan Gao
- Baoping Liu
View Affiliations

Affiliations: Department of Radiology, The First Affiliated Hospital of Henan University of Technology and Science, Luoyang, Henan 471003, P.R. China, Department of Imaging and Nuclear Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China, Department of Oncology, The First Affiliated Hospital of Henan University of Technology and Science, Luoyang, Henan 471003, P.R. China
Published online on: April 23, 2013 https://doi.org/10.3892/or.2013.2418
Pages: 246-252

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatocellular carcinoma (HCC) is a major health problem worldwide. CD147 has been reported to be overexpressed in HCC and blocking CD147 expression can decrease tumor growth. 131I is often used in combination with other drugs to treat HCC and yields positive results. In this study, we combined the 131I and CD147 monoclonal antibody to treat HCC in a rabbit VX2 animal model. In the 131I-labeled CD147 antibody (131I-CD147-Ab) treatment group, the animals lived considerably longer than the animals in the other treatment groups. Metastasis and tumor growth in the 131I-CD147-Ab treatment group were also inhibited. MMP2 and CD31 expression were significantly lower in the treatment group, whereas Tunel staining was overexpressed. These findings suggest that 131I-CD147-Ab is a promising drug in the treatment of HCC, by inhibiting metastasis and growth and by decreasing the expression of MMP2 and CD31 or by inducing tumor necrosis. After testing the biochemical parameters, 131I-CD147-Ab caused fewer side-effects in the animals.

View Figures

View References

1	Parkin DM, Bray F, Ferlay J and Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer. 94:153–156. 2001. View Article : Google Scholar : PubMed/NCBI
2	Llovet JM, Burroughs A and Bruix J: Hepatocellular carcinoma. Lancet. 362:1907–1917. 2003. View Article : Google Scholar
3	Jelic S: Hepatocellular carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 20(Suppl 4): 41–45. 2009. View Article : Google Scholar : PubMed/NCBI
4	Lai EC, Fan ST, Lo CM, Chu KM, Liu CL and Wong J: Hepatic resection for hepatocellular carcinoma. An audit of 343 patients. Ann Surg. 221:291–298. 1995. View Article : Google Scholar : PubMed/NCBI
5	No authors listed. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d’Etude et de Traitement du Carcinome Hepatocellulaire. N Engl J Med. 332:1256–1261. 1995.
6	Schwartz JD and Beutler AS: Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials-II: systemic and local non-embolization-based therapies in unresectable and advanced hepatocellular carcinoma. Anticancer Drugs. 15:439–452. 2004. View Article : Google Scholar
7	Biswas C: Tumor cell stimulation of collagenase production by fibroblasts. Biochem Biophys Res Commun. 109:1026–1034. 1982. View Article : Google Scholar
8	Biswas C, Zhang Y, DeCastro R, et al: The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res. 55:434–439. 1995.PubMed/NCBI
9	Philp NJ, Ochrietor JD, Rudoy C, Muramatsu T and Linser PJ: Loss of MCT1, MCT3, and MCT4 expression in the retinal pigment epithelium and neural retina of the 5A11/basigin-null mouse. Invest Ophthalmol Vis Sci. 44:1305–1311. 2003. View Article : Google Scholar : PubMed/NCBI
10	Guo H, Zucker S, Gordon MK, Toole BP and Biswas C: Stimulation of matrix metalloproteinase production by recombinant extracellular matrix metalloproteinase inducer from transfected Chinese hamster ovary cells. J Biol Chem. 272:24–27. 1997. View Article : Google Scholar
11	Zhu S, Li Y, Mi L, et al: Clinical impact of HAb18G/CD147 expression in esophageal squamous cell carcinoma. Dig Dis Sci. 56:3569–3576. 2011. View Article : Google Scholar : PubMed/NCBI
12	Zhong WD, Liang YX, Lin SX, et al: Expression of CD147 is associated with prostate cancer progression. Int J Cancer. 130:300–308. 2012. View Article : Google Scholar : PubMed/NCBI
13	Liu F, Cui L, Zhang Y, et al: Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma. Breast Cancer Res Treat. 124:677–688. 2010. View Article : Google Scholar : PubMed/NCBI
14	He HC, Han ZD, Dai QS, et al: Expression and significance of CD147 protein in prostate cancer. Zhonghua Yi Xue Za Zhi. 89:1844–1846. 2009.(In Chinese).
15	Xu J, Xu HY, Zhang Q, et al: HAb18G/CD147 functions in invasion and metastasis of hepatocellular carcinoma. Mol Cancer Res. 5:605–614. 2007. View Article : Google Scholar : PubMed/NCBI
16	Redondo P, Lloret P, Idoate M and Inoges S: Expression and serum levels of MMP-2 and MMP-9 during human melanoma progression. Clin Exp Dermatol. 30:541–545. 2005. View Article : Google Scholar
17	Kawamura K, Kamiya N, Suyama T, et al: In situ gelatinolytic activity correlates with tumor progression and prognosis in patients with bladder cancer. J Urol. 172:1480–1484. 2004. View Article : Google Scholar : PubMed/NCBI
18	Sun J and Hemler ME: Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions. Cancer Res. 61:2276–2281. 2001.PubMed/NCBI
19	Xu J, Shen ZY, Chen XG, et al: A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation. Hepatology. 45:269–276. 2007. View Article : Google Scholar : PubMed/NCBI
20	Kanekura T, Chen X and Kanzaki T: Basigin (CD147) is expressed on melanoma cells and induces tumor cell invasion by stimulating production of matrix metalloproteinases by fibroblasts. Int J Cancer. 99:520–528. 2002. View Article : Google Scholar : PubMed/NCBI
21	Llovet JM, Real MI, Montana X, et al: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 359:1734–1739. 2002. View Article : Google Scholar
22	Hansler J, Neureiter D, Wasserburger M, et al: Percutaneous US-guided radiofrequency ablation with perfused needle applicators: improved survival with the VX2 tumor model in rabbits. Radiology. 230:169–174. 2004. View Article : Google Scholar : PubMed/NCBI
23	Yoon CJ, Chung JW, Park JH, et al: Transcatheter arterial chemoembolization with paclitaxel-lipiodol solution in rabbit VX2 liver tumor. Radiology. 229:126–131. 2003. View Article : Google Scholar : PubMed/NCBI
24	Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar
25	Zhang Z, Bian H, Feng Q, et al: Biodistribution and localization of iodine-131-labeled metuximab in patients with hepatocellular carcinoma. Cancer Biol Ther. 5:318–322. 2006. View Article : Google Scholar : PubMed/NCBI
26	Yamaguchi R, Yano H, Iemura A, Ogasawara S, Haramaki M and Kojiro M: Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology. 28:68–77. 1998. View Article : Google Scholar : PubMed/NCBI
27	Weidner N, Semple JP, Welch WR and Folkman J: Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med. 324:1–8. 1991. View Article : Google Scholar : PubMed/NCBI
28	Hamaguchi S, Tohnai I, Ito A, et al: Selective hyperthermia using magnetoliposomes to target cervical lymph node metastasis in a rabbit tongue tumor model. Cancer Sci. 94:834–839. 2003. View Article : Google Scholar : PubMed/NCBI
29	Marelli L, Stigliano R, Triantos C, et al: Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol. 30:6–25. 2007. View Article : Google Scholar : PubMed/NCBI
30	Biolato M, Marrone G, Racco S, et al: Transarterial chemoembolization (TACE) for unresectable HCC: a new life begins? Eur Rev Med Pharmacol Sci. 14:356–362. 2010.PubMed/NCBI
31	Yang Y, Lu N, Zhou J, Chen ZN and Zhu P: Cyclophilin A up-regulates MMP-9 expression and adhesion of monocytes/macrophages via CD147 signalling pathway in rheumatoid arthritis. Rheumatology. 47:1299–1310. 2008. View Article : Google Scholar : PubMed/NCBI
32	Dai JY, Dou KF, Wang CH, et al: The interaction of HAb18G/CD147 with integrin alpha6beta1 and its implications for the invasion potential of human hepatoma cells. BMC Cancer. 9:3372009. View Article : Google Scholar : PubMed/NCBI
33	Zhou J, Zhu P, Jiang JL, et al: Involvement of CD147 in overexpression of MMP-2 and MMP-9 and enhancement of invasive potential of PMA-differentiated THP-1. BMC Cell Biol. 6:252005. View Article : Google Scholar : PubMed/NCBI
34	Stewart CJ and Crook ML: CD147 (EMMPRIN) and matrix metalloproteinase-2 expression in uterine endometrioid adenocarcinoma. Pathol Res Pract. 207:30–36. 2011. View Article : Google Scholar : PubMed/NCBI
35	Afonso J, Longatto-Filho A, Baltazar F, et al: CD147 overexpression allows an accurate discrimination of bladder cancer patients’ prognosis. Eur J Surg Oncol. 37:811–817. 2011.PubMed/NCBI
36	Voigt H, Vetter-Kauczok CS, Schrama D, Hofmann UB, Becker JC and Houben R: CD147 impacts angiogenesis and metastasis formation. Cancer Invest. 27:329–333. 2009. View Article : Google Scholar : PubMed/NCBI